Pacira BioSciences, Inc. PCRX
Set alert
At close · Nov 2
After hours · Nov 2, 4:29 PM ET
- YTD
- +40.65%
- 1 year
- +70.25%
- Open
- 36.41
- Prev close
- 36.39
- Mkt cap
- 1.45B
- Vol
- 810.93K
- Avg vol
- 1.26M
- EPS
- 0.35
- P/E
- 104.00
- Div yield
- 0.00%
More statistics
- Low
- 36.38
- High
- 36.41
- Forward P/E
- 10.52
- Beta
- 0.22
- Short ratio
- 1.89
- Inst. own
- 106.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 29.06
- 200-d avg
- 24.84
- 1y target
- 33.57
News
2 days ago businesswire.com
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash. Halper…
-
3 days ago benzinga.com
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
3 days ago prnewswire.com
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary…
2 weeks ago benzinga.com
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.
3 weeks ago gurufocus.com
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
3 weeks ago prnewswire.com
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
3 weeks ago businesswire.com
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
3 weeks ago gurufocus.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)PR NewswireNEW YORK, Oct. 11, 2026NEW YORK, Oc
3 weeks ago prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)
NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
-
3 weeks ago benzinga.com
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5
Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.
3 weeks ago zacks.com
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.
3 weeks ago benzinga.com
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
3 weeks ago benzinga.com
CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5
HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.
3 weeks ago benzinga.com
Nasdaq Falls Over 300 Points as Oil Prices Surge: Investor Sentiment Weakens, Fear & Greed Index Remains in ‘Fear’ Zone
Markets stayed fearful as index fell to 38; Dow gained, S&P/Nasdaq slipped amid oil surge and Iran tensions. PepsiCo and Pacira shares rose.
3 weeks ago newsfilecorp.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Pacira BioSciences,…
-
3 weeks ago benzinga.com
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target
Jefferies analyst Glen Santangelo downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and announces $36 price target.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose…
3 weeks ago gurufocus.com
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.PR NewswireMILWAUKEE, Oct. 8, 2026PCRX shareholders will rec
3 weeks ago benzinga.com
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
3 weeks ago prnewswire.com
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.
PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and…
3 weeks ago benzinga.com
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
3 weeks ago schaeffersresearch.com
2 Stocks Drawing Bearish Options Activity Today
Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira BioSciences Inc (NASDAQ:PCRX) and Ring Energy Inc (NYSEAMERICAN:REI).
3 weeks ago benzinga.com
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira soared 44.1% on Viatris acquisition news.
3 weeks ago gurufocus.com
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash
3 weeks ago wsj.com
Viatris to Buy Pacira BioSciences for $1.65 Billion
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
3 weeks ago businesswire.com
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc. (NASDAQ: PCRX) to Viatris Inc. for $36.50 per share in cash.Halper…
3 weeks ago prnewswire.com
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International…
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Pacira BioSciences, Raises Price Target to $31
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $31.
3 weeks ago globenewswire.com
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE…
3 weeks ago zacks.com
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
4 weeks ago globenewswire.com
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader…
1 month ago defenseworld.net
240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE
Bank of America Corp DE bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) during the second quarter, according to the company in its most recent disclosure with the…
-
1 month ago benzinga.com
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32
Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
-
2 months ago benzinga.com
Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —— Exploratory clinical outcome measures…
-
2 months ago benzinga.com
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $25
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $24 to $25.
-
2 months ago benzinga.com
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $33
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $32 to $33.
-
3 months ago benzinga.com
Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est
Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.
-
3 months ago benzinga.com
Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate
Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.65 by 12.31 percent. This is a 1.35 percent decrease over earnings of…
-
3 months ago benzinga.com
Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026
With drug product from the new manufacturing process now available, the first patient has been enrolled in Part B of the Phase 2 ASCEND study. Enrollment in Part A of ASCEND concluded in June, with…
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $38 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintains $38 price target.
-
4 months ago benzinga.com
Pacira BioSciences Says UnitedHealthcare Now Provides Separate Reimbursement For EXPAREL Across Outpatient Settings, Including Hospital Outpatient Departments And Ambulatory Surgery Centers
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the…
-
4 months ago benzinga.com
Pacira BioSciences Divests Iovera To Zimmer Biomet For Up To $140M
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of…
-
5 months ago benzinga.com
Pacira BioSciences Announces Findings From Real-World Study Evaluating Outcomes Associated With Use Of EXPAREL Following Outpatient Total Shoulder Arthroplasty In Medicare Advantage Patients
Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL useBRISBANE, Calif., May 27, 2026 (GLOBE…
-
6 months ago benzinga.com
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $24
RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $22 to $24.
-
6 months ago benzinga.com
Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $32
Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises the price target from $30 to $32.
-
6 months ago benzinga.com
Pacira BioSciences Q1 2026 Earnings Call Transcript
Pacira BioSciences Q1 2026 Earnings Call Transcript
-
6 months ago benzinga.com
Pacira BioSciences Affirms FY2026 Sales Guidance of $745.000M-$770.000M vs $759.317M Est
Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in millions)2026 Financial GuidanceAmountEXPAREL net product sales$600 to $620Total revenues$745 to…